Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

NCT05326243 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Large B-cell Lymphoma
Follicular Lymphoma Grade 3A
Follicular Lymphoma Grade 3B

Interventions

BIOLOGICAL: CD19-targeted chimeric antigen receptor T-cell

Sponsor

Pell Bio-Med Technology Co., Ltd.